EKElena Kum

Elena Kum

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Elena Kum has a total of 127 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Multicentre, 2×2 factorial, randomised, open-label trial of neuromodulators and cough control therapy for refractory or unexplained chronic cough: the FORTITUDE trial protocol

    by Elena Kum, Wafa Hassan, Sue Beaudin, Geoff Strong, Kim Smith, Ana Oliveira, Mustafa Al-Saiedy, Renata Mancopes, Ana Sofia Grave, Melanie Bernier, et al.

    Introduction: While clinicians commonly prescribe neuromodulators for the treatment of refractory or unexplained chronic cough, no trials have directly compared these treatments. Furthermore, although guidelines recommend non-pharmacological management involving physiotherapy and speech-language therapy, few trials have evaluated its effectiveness. Methods and analysis: FORTITUDE ( F act O rial R andomized T r I al T o eval U ate neuromo D ulators and cough control th E rapy) is a 6-week, 2×2 factorial, randomised, open-label trial with an observational extension up to 1 year. The trial will include Canadian hospital sites enrolling 124 patients. Patients ≥18 years old with either refractory or unexplained chronic cough will undergo independent 1:1 randomisation to pharmacotherapy—either low-dose morphine (up to 5 mg two times per day) or pregabalin (up to 150 mg two times per day)—and concurrent cough control therapy (CCT) or no CCT. The CCT will consist of five virtual sessions delivered over 6 weeks by a trained physiotherapist or speech-language pathologist. Change from baseline in 24-hour cough frequency at 6 weeks represents the primary outcome. Secondary outcomes include change from baseline in awake, sleep and cough bout frequencies; cough severity on the McMaster Cough Severity Questionnaire and the 100-mm Visual Analogue Scale; and cough quality of life on the Leicester Cough Questionnaire at 6 weeks. We will analyse safety and tolerability at 6 weeks and explore potential interactions between neuromodulators and CCT. Follow-up in an observational extension of up to 12 months post-randomisation will assess long-term treatment patterns, adherence and safety in a real-world setting. Ethics and dissemination: Health Canada’s Pharmaceutical Drugs Directorate has provided approval to conduct this study. We have approval from the Hamilton Integrated Research Ethics Board of the Main Coordinating Site, with ethics pending at other participating sites. Results of the main trial and the observational extension will be published as manuscripts in peer-reviewed journals. Trial registration number: NCT07288528 .

  • The design of studies testing the effectiveness of risk-guided care has many challenges: a scoping review addressing key considerations

    by Ana C. Alba, Andrea J. Darzi, Tayler A. Buchan, Elena Kum, Kathryn Uhlman, Natasha Aleksova, Ani Orchanian-Cheff, Lakshmi Kugathasan, Farid Foroutan, Thomas McGinn, et al.


  • An extension minimal important difference credibility item addressing construct proximity is a reliable alternative to the correlation item

    by Yuting Wang, Tahira Devji, Alonso Carrasco-Labra, Anila Qasim, Qiukui Hao, Elena Kum, Niveditha Devasenapathy, Madeleine T. King, Berend Terluin, Caroline B. Terwee, et al.


  • Canadian Health Care Professionals’ Familiarity with Chronic Cough Guidelines and Experiences with Diagnosis and Management: A Cross-Sectional Survey

    by Elena Kum, Danica Brister, Nermin Diab, Mustafaa Wahab, Ted Abraham, Sevag Sahakian, Kaiser Qureshy, Paul Hernandez, Harold Kim, Maxime Cormier, et al.

    Introduction Educational programs on chronic cough may improve patient care, but little is known about how Canadian physicians manage this common debilitating condition. We aimed to investigate Canadian physicians’ perceptions, attitudes, and knowledge of chronic cough. Methods We administered a 10-min anonymous, online, cross-sectional survey to 3321 Canadian physicians in the Leger Opinion Panel who managed adult patients with chronic cough and had been in practice for > 2 years. Results Between July 30 and September 22, 2021, 179 physicians (101 general practitioners [GPs] and 78 specialists [25 allergists, 28 respirologists, and 25 ear/nose/throat specialists]) completed the survey (response rate: 5.4%). In a month, GPs saw a mean of 27 patients with chronic cough, whereas specialists saw 46. About one-third of physicians appropriately identified a duration of > 8 weeks as the definition for chronic cough. Many physicians reported not using international chronic cough management guidelines. Patient referrals and care pathways varied considerably, and patients frequently experienced lost to follow-up. While physicians endorsed nasal and inhaled corticosteroids as common treatments for chronic cough, they rarely used other guideline-recommended treatments. Both GPs and specialists expressed high interest in education on chronic cough. Conclusion This survey of Canadian physicians demonstrates low uptake of recent advances in chronic cough diagnosis, disease categorization, and pharmacologic management. Canadian physicians also report unfamiliarity with guideline-recommended therapies, including centrally acting neuromodulators for refractory or unexplained chronic cough. This data highlights the need for educational programs and collaborative care models on chronic cough in primary and specialist care.


  • Why We Swab: A library of stories in stem cell donation

    by Gabriele Jagelaviciute, Elena Kum, Edward W. Li, Aaron Rosenfeld, Kenneth Williams, Rana Kandel, Natalie DeGurse, Brady Park, Sylvia Okonofua, Lauren Sano, et al.

    Background: Stories are powerful in their ability to disseminate information in a meaningful way. We hypothesized that a stem cell donation story library optimized for social media could support the education and recruitment of committed unrelated hematopoietic stem cell donors from needed demographic groups.Study Design and Methods: We developed Why We Swab, a library of stories on stem cell donation (facebook.com/WhyWeSwab; instagram.com/WhyWeSwab; twitter.com/WhyWeSwab), and evaluated its impact across social and traditional media as well as on eligible potential donors' knowledge and attitudes towards donation.Results: As of December 2021, the library included 28 story arcs featuring 45 storytellers from diverse ancestral backgrounds, including 8 donor‐recipient stories. Overall, the stories reached >92,000 people across social media. Notably, stories were republished by 18 print/ broadcast media outlets in Canada and by major medical organizations. A series of stories shown to 33 eligible potential donors improved mean total scores on a donation knowledge test (64% to 85%, p < 0.001), reduced mean ambivalence scale scores (3.85 to 2.70, p < 0.001), and improved participants' willingness to register as donors (45% to 73%, p < 0.005). Data are also shown demonstrating that stakeholders valued the library and that its deployment was associated with improved donor recruitment outcomes in Canada.Conclusion: Why We Swab is accessible and relevant to a wide audience, including stem cell donor registries and recruitment organizations seeking to improve their recruitment efforts as well as to blood and organ & tissue donation organizations who can adapt the Why We Swab model to their audiences.


  • Open Access

    Assessing cough symptom severity in refractory or unexplained chronic cough: findings from patient focus groups and an international expert panel

    by Elena Kum, Gordon H. Guyatt, Caroline Munoz, Suzanne Beaudin, Shelly-Anne Li, Rayid Abdulqawi, Huda Badri, Louis-Philippe Boulet, Ruchong Chen, Peter Dicpinigaitis, et al.

    Background: Cough symptom severity represents an important subjective end-point to assess the impact of therapies for patients with refractory or unexplained chronic cough (RCC/UCC). As existing instruments assessing the severity of cough are neither widely available nor tested for measurement properties, we aim to develop a new patient-reported outcome measure addressing cough severity.Objective: The aim of this study was to establish items and domains that would inform development of a new cough severity instrument.Methods: Three focus groups involving 16 adult patients with RCC/UCC provided data that we analysed using directed content analysis. Discussions led to consensus among an international panel of 15 experts on candidate items and domains to assess cough severity.Results: The patient focus group provided 48 unique items arranged under broad domains of urge-to-cough sensations and cough symptom. Feedback from expert panel members confirmed the appropriateness of items and domains, and provided an additional subdomain related to cough triggers. The final conceptual framework comprised 51 items in the following domains: urge-to-cough sensations (subdomains: frequency and intensity) and cough symptom (subdomains: triggers, control, frequency, fit/bout duration, intensity, quality and associated features/sequelae).Conclusions: Consensus findings from patients and international experts established domains of urge-to-cough and cough symptom with associated subdomains and relevant items. The results support item generation and content validity for a novel patient-reported outcome measure for use in health research and clinical practice.


  • Development and evaluation of a community of practice to improve stem cell donor recruitment in Canada

    by Elena Kum, Gabriele Jagelaviciute, Angela C. Chen, Iman Baharmand, Samer Rihani, Gabriella Rumball, Div Patel, Rana Kandel, Sylvia Okonofua, Edward W. Li, et al.

    Background and Objectives: Communities of practice (CoPs) represent effective models to achieve quality outcomes in health care. We report the development and evaluation of a CoP to improve stem cell donor recruitment in Canada.Materials and Methods: In September 2017, we invited national stakeholders in stem cell donor recruitment to participate in a Facebook group and regular e‐meetings. E‐meetings involved speakers and roundtable discussion on topics related to donor recruitment. The Facebook group facilitated sharing of resources. We evaluated stakeholder perspective of the CoP and the impact on recruitment outcomes.Results: As of December 2020, the CoP included 382 members who published 243 posts to the Facebook group about patient/donor stories (40%), resources (27%), updates/questions (21%) and recruitment outcomes (12%). In January 2020, we surveyed 44 CoP participants; the majority felt that the Facebook group (86%) and e‐meetings (59%) supported the community, and that the CoP fostered collaboration (82%), improved their donor recruitment knowledge (75%) and practice (77%) and improved their ability to recruit needed donors (64%). The launch of the CoP correlated with improved donor recruitment outcomes. In 2016–2017, CoP participants recruited 2918 registrants (46% male; 55.9% non‐Caucasian) compared to 4531 registrants in 2018–2019 (52.9% male; 62.7% non‐Caucasian). Members of the CoP developed innovative resources to support recruitment efforts and led national campaigns securing coverage in major media outlets.Conclusion: We describe the first CoP in stem cell donor recruitment to be formally evaluated. The CoP model may be adopted by donor recruitment organisations, registries and blood banks worldwide to improve recruitment outcomes.Highlights: • A community of practice (CoP) in stem cell donor recruitment was valued by participants and supported efforts to improve recruitment outcomes.• The CoP model may be adopted by donor recruitment organizations, donor registries, and blood banks worldwide to improve recruitment outcomes.


  • Open Access

    Chronic cough: Investigations, management, current and future treatments

    by I. Satia, M. Wahab, E. Kum, H. Kim, P. Lin, A. Kaplan, P. Hernandez, J. Bourbeau, L. P. Boulet, S. K. Field

    Chronic cough, defined as cough lasting 8 weeks or longer, is a condition for which there is currently no licensed treatment. Chronic cough affects approximately 16% of Canadian adults between the age of 45 and 85 years and is often associated with physical, social, and psychological impairments. The purpose of this state-of-the-art review is to highlight the investigations, management, current and future treatment options and mechanistic concepts underlying chronic cough. Assessments of chronic cough should include a detailed history and examination to identify potential causes and triggers. Conditions associated with chronic cough include ACE inhibitor use, smoking, asthma, non-asthmatic eosinophilic bronchitis, gastroesophageal reflux disease, and upper airways cough syndrome. The impact and severity of chronic cough can be assessed in clinic using subjective questionnaires. Persistent cough despite optimal treatment of the underlying condition is called refractory chronic cough (RCC). Persistent cough for which no underlying cause is found, is labeled unexplained chronic cough (UCC). If treatment of underlying disease is unsuccessful at controlling cough despite adequate duration and adherence to the treatment, neuromodulator treatments such as speech and language therapy and/or low dose opioid, gabapentin, and pregabalin may be therapeutic options. There is no licensed treatment for RCC/UCC but a new class of medication targeting the purinergic P2X3 receptor is currently under consideration for regulatory approval with other P2X3 antagonists in phase 2 and phase 3 clinical development. Approval of this new treatment class may represent a hopeful advancement for patients suffering with chronic cough. RÉSUMÉ La toux chronique, définie comme une toux qui dure huit semaines ou plus, est une affection pour laquelle il n’existe actuellement aucun traitement autorisé. La toux chronique affecte environ 16 % des adultes canadiens âgés de 45 à 85 ans et est souvent associée à des déficiences physiques, sociales et psychologiques. Le but de cette revue de l’état de l’art est de mettre en évidence les investigations, la prise en charge, les options de traitement actuelles et futures et les concepts mécanistes sous-jacents à la toux chronique. Les évaluations de la toux chronique devraient inclure un historique détaillé et un examen pour déterminer les causes et les déclencheurs potentiels. Les affections associées à la toux chronique comprennent l’utilisation d’inhibiteurs de l’ECA, le tabagisme, l’asthme, la bronchite éosinophile non asthmatique, le reflux gastro-oesophagien et le syndrome de toux des voies respiratoires supérieures. L’impact et la gravité de la toux chronique peuvent être évalués en clinique à l’aide de questionnaires subjectifs. Une toux persistante malgré un traitement optimal de l’affection sous-jacente est appelée toux chronique réfractaire (TCR). La toux persistante pour laquelle aucune cause sous-jacente n’est trouvée, est appelée toux chronique inexpliquée (TCI). Si le traitement de la maladie sous-jacente ne parvient pas à maîtriser la toux malgré une durée et une adhésion adéquates au traitement, les traitements par neuromodulateurs tels que l’orthophonie et/ou les opioïdes à faible dose, la gabapentine et la prégabaline peuvent être des options thérapeutiques. Il n’y a pas de traitement autorisé pour la TCR/TCI, mais une nouvelle classe de médicaments ciblant le récepteur purinergique P2X3 est actuellement à l’étude pour approbation réglementaire, avec d’autres antagonistes P2X3 en phase 2 et 3 de développement clinique. L’approbation de cette nouvelle classe de traitement peut représenter une avancée prometteuse pour les patients souffrant de toux chronique.


  • Open Access

    Donor–Recipient Story in Allogeneic Hematopoietic Stem Cell Transplantation

    by Elena Kum, Gabriele Jagelaviciute, Edward Li, Kenneth Williams, Santhosh Thyagu, Warren Fingrut

    Patients with a variety of blood, immune, and metabolic disorders may require an allogeneic hematopoietic stem cell transplant as part of their treatment. However, over 70% of these patients do not have a matched sibling donor and require an alternative donor, such as a matched unrelated donor. We present a multi-part story of a Canadian stem cell recipient who underwent transplantation for treatment of refractory chronic myelogenous leukemia, and the matched unrelated donor who saved his life. The story segments feature excerpts from interviews with the donor and the recipient, along with representative images of both storytellers. The excerpts were optimized for publication on social media and were arranged to build a story arc that parallels the journey of the donor and recipient together. This donor-recipient story may serve as a resource to help raise awareness about stem cell donation and to encourage eligible individuals to register as donors. The story is one of several developed by Why We Swab, a library of stories in stem cell donation in Canada (Facebook, Twitter, and Instagram; @WhyWeSwab) to support the recruitment of committed unrelated donors.


  • Multimedia resources to support the recruitment of committed hematopoietic stem cell donors: Perspectives of the most‐needed donors

    by Edward W. Li, Anna Lee, Maryam Vaseghi‐Shanjani, Alexander Anagnostopoulos, Gabriele Jagelaviciute, Elena Kum, Tanya Petraszko, Heidi Elmoazzen, David Allan, Warren Fingrut

    Background: Recruitment of committed unrelated hematopoietic stem cell donors from the most‐needed demographics remains a challenge for donor recruitment organizations worldwide. Multimedia resources are gaining attention as a modality to support recruitment efforts; however, there is a lack of guidance for the development of such tools. This qualitative study explores the perspectives of eligible stem cell donors on an educational whiteboard video about stem cell donation, generating insights into how whiteboard videos and related multimedia may be optimized for donor recruitment.Study Design and Methods: Eight semistructured focus groups were conducted with 38 potential donors from the most‐needed demographics (young, male, and non‐Caucasian) after they had watched a 3.5‐minute whiteboard video explaining key concepts in stem cell donation (https://youtu.be/V4fVBtxnWfM). Constructivist grounded theory was used to identify themes and to develop a framework for understanding participants' preferred features of recruitment multimedia.Results: Participants identified a range of features contributing to the effectiveness of recruitment multimedia, adding that the whiteboard video is an effective, integrated, and readily accessible format for supporting donor recruitment. Topics that participants felt are important to address include knowledge gaps regarding donation procedures, concerns about donor safety, and the particular need for specific donor demographics. Suggested avenues for improvement include the addition of donor/recipient/patient personal experiences, attention‐grabbing hooks, and a call to action including opportunities for further learning.Conclusions: Several considerations were generated to inform the development of future multimedia for donor education/recruitment and are relevant to donor recruitment organizations worldwide.